Genetics of Gastric Cancer

• Published in: The Surgical clinics of North America Vol. 97; no. 2; p. 345
• Main Authors: Strand, Matthew S, Lockhart, Albert Craig, Fields, Ryan C
• Format: Journal Article
• Language: English
• Published: United States 01.04.2017
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - mortality; Adenocarcinoma - therapy; Antineoplastic Agents - therapeutic use; Biological Products - therapeutic use; Early Detection of Cancer - methods; Fibroblast Growth Factor 2 - antagonists & inhibitors; Gastrectomy - methods; Gastrectomy - mortality; Hedgehog Proteins - genetics; Humans; Immunotherapy - methods; MAP Kinase Signaling System - genetics; Molecular Targeted Therapy - methods; Molecular Targeted Therapy - mortality; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, ErbB-2 - antagonists & inhibitors; Stomach Neoplasms - genetics; Stomach Neoplasms - mortality; Stomach Neoplasms - therapy; Survival Analysis; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Hereditary gastric cancer syndromes; Targeted therapy; Immunotherapy; Genetics; Gastric adenocarcinoma; Gastric cancer; Prophylactic gastrectomy
• ISSN: 1558-3171
• DOI: 10.1016/j.suc.2016.11.009

Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.